Evan Seigerman
Stock Analyst at BMO Capital
(4.82)
# 482
Out of 5,119 analysts
1124
Total ratings
58.7%
Success rate
11.8%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Reiterated: Hold | $40 → $44 | $40.31 | +9.15% | 62 | Nov 5, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $178 → $190 | $132.04 | +43.90% | 7 | Nov 5, 2026 | |
| SDGR Schrödinger | Rated: Buy | $30 → $35 | $29.82 | +17.37% | 21 | Nov 5, 2026 | |
| AMGN Amgen | Reiterated: Hold | $415 → $442 | $460.42 | -4.00% | 74 | Nov 4, 2026 | |
| PFE Pfizer | Reiterated: Buy | $35 | $29.39 | +19.09% | 58 | Nov 4, 2026 | |
| BNTX BioNTech SE | Rated: Hold | $105 → $95 | $87.51 | +8.56% | 20 | Nov 3, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $600 → $620 | $547.09 | +13.33% | 74 | Nov 3, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $300 → $340 | $291.31 | +16.71% | 31 | Nov 2, 2026 | |
| BIIB Biogen | Reiterated: Hold | $250 | $248.35 | +0.66% | 67 | Nov 2, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $60 | $62.14 | -3.44% | 73 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $174 → $184 | $166.89 | +10.25% | 84 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $130 | $119.65 | +8.65% | 58 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,400 → $1,650 | $1,354.00 | +21.86% | 124 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $150 | $164.63 | -8.89% | 50 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $920 → $1,050 | $904.35 | +16.11% | 82 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $170 | $146.73 | +15.86% | 56 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $21.62 | -7.49% | 36 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $120 | $78.91 | +52.07% | 32 | Oct 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $310 | $132.37 | +134.19% | 1 | Oct 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $46.94 | +78.95% | 14 | Oct 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $11.88 | +26.26% | 12 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $6.93 | +188.60% | 3 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39.00 → $43.00 | $34.48 | +24.71% | 2 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $145 | $20.35 | +612.53% | 21 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $4.33 | +223.33% | 9 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $34 | $21.23 | +60.15% | 8 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.41 | n/a | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.31 | n/a | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.10 | n/a | 1 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €117.75 → €133.81 | €148.75 | n/a | 3 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.75 | n/a | 5 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.16 | n/a | 3 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 → $27 | $4.11 | n/a | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $9 → $15 | $13.87 | n/a | 6 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €135.00 → €129.00 | €29.62 | n/a | 6 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $0.69 → $0.84 | $1.05 | n/a | 6 | Aug 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $30 | $2.33 | n/a | 4 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $169 → $220 | $33.45 | n/a | 2 | Feb 24, 2020 |
Novo Nordisk
Nov 5, 2026
Reiterated: Hold
Price Target: $40 → $44
Current: $40.31
Upside: +9.15%
Protagonist Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $178 → $190
Current: $132.04
Upside: +43.90%
Schrödinger
Nov 5, 2026
Rated: Buy
Price Target: $30 → $35
Current: $29.82
Upside: +17.37%
Amgen
Nov 4, 2026
Reiterated: Hold
Price Target: $415 → $442
Current: $460.42
Upside: -4.00%
Pfizer
Nov 4, 2026
Reiterated: Buy
Price Target: $35
Current: $29.39
Upside: +19.09%
BioNTech SE
Nov 3, 2026
Rated: Hold
Price Target: $105 → $95
Current: $87.51
Upside: +8.56%
Vertex Pharmaceuticals
Nov 3, 2026
Reiterated: Buy
Price Target: $600 → $620
Current: $547.09
Upside: +13.33%
AbbVie
Nov 2, 2026
Reiterated: Buy
Price Target: $300 → $340
Current: $291.31
Upside: +16.71%
Biogen
Nov 2, 2026
Reiterated: Hold
Price Target: $250
Current: $248.35
Upside: +0.66%
Bristol-Myers Squibb Company
Nov 2, 2026
Reiterated: Hold
Price Target: $60
Current: $62.14
Upside: -3.44%
Nov 2, 2026
Reiterated: Buy
Price Target: $174 → $184
Current: $166.89
Upside: +10.25%
Nov 2, 2026
Reiterated: Hold
Price Target: $130
Current: $119.65
Upside: +8.65%
Nov 2, 2026
Reiterated: Buy
Price Target: $1,400 → $1,650
Current: $1,354.00
Upside: +21.86%
Nov 2, 2026
Reiterated: Hold
Price Target: $150
Current: $164.63
Upside: -8.89%
Nov 2, 2026
Reiterated: Buy
Price Target: $920 → $1,050
Current: $904.35
Upside: +16.11%
Oct 30, 2026
Reiterated: Buy
Price Target: $170
Current: $146.73
Upside: +15.86%
Oct 28, 2026
Reiterated: Buy
Price Target: $20
Current: $21.62
Upside: -7.49%
Oct 19, 2026
Reiterated: Buy
Price Target: $100 → $120
Current: $78.91
Upside: +52.07%
Oct 12, 2026
Reiterated: Buy
Price Target: $310
Current: $132.37
Upside: +134.19%
Oct 12, 2026
Reiterated: Buy
Price Target: $84
Current: $46.94
Upside: +78.95%
Aug 17, 2026
Reiterated: Buy
Price Target: $15
Current: $11.88
Upside: +26.26%
Aug 13, 2026
Reiterated: Buy
Price Target: $20
Current: $6.93
Upside: +188.60%
Aug 12, 2026
Reiterated: Buy
Price Target: $39.00 → $43.00
Current: $34.48
Upside: +24.71%
Aug 6, 2026
Reiterated: Buy
Price Target: $145
Current: $20.35
Upside: +612.53%
Jun 30, 2026
Reiterated: Buy
Price Target: $14
Current: $4.33
Upside: +223.33%
May 11, 2026
Reiterated: Buy
Price Target: $26 → $34
Current: $21.23
Upside: +60.15%
Sep 30, 2025
Rated: Hold
Price Target: n/a
Current: $6.41
Upside: n/a
Sep 30, 2025
Rated: Hold
Price Target: n/a
Current: $25.31
Upside: n/a
May 6, 2025
Rated: Hold
Price Target: n/a
Current: $3.10
Upside: n/a
Oct 23, 2024
Reiterated: Buy
Price Target: €117.75 → €133.81
Current: €148.75
Upside: n/a
Aug 7, 2023
Rated: Hold
Price Target: n/a
Current: $8.75
Upside: n/a
May 9, 2023
Rated: Hold
Price Target: n/a
Current: $4.16
Upside: n/a
Aug 13, 2021
Reiterated: Buy
Price Target: $30 → $27
Current: $4.11
Upside: n/a
Dec 16, 2020
Upgraded: Buy
Price Target: $9 → $15
Current: $13.87
Upside: n/a
Oct 16, 2020
Reiterated: Hold
Price Target: €135.00 → €129.00
Current: €29.62
Upside: n/a
Aug 13, 2020
Reiterated: Sell
Price Target: $0.69 → $0.84
Current: $1.05
Upside: n/a
May 11, 2020
Reiterated: Buy
Price Target: $13 → $30
Current: $2.33
Upside: n/a
Feb 24, 2020
Reiterated: Hold
Price Target: $169 → $220
Current: $33.45
Upside: n/a